Bazdaca ML 200mg Injection

About

Bazdaca ML 200mg Injection, likely containing Dacarbazine, is an intravenous cytotoxic chemotherapy agent classified as an alkylating agent, primarily used in the treatment of metastatic malignant melanoma and as a component of combination regimens for Hodgkin's lymphoma. It functions as a prodrug, requiring metabolic activation in the liver by cytochrome P450 enzymes to form its active metabolite, methyltriazenoimidazole carboxamide (MTIC). This active metabolite then acts as an alkylating agent, interfering with DNA synthesis and function by methylating guanine residues in DNA. This damage to DNA leads to cell cycle arrest and ultimately apoptosis of rapidly dividing cancer cells, thereby inhibiting tumor growth and progression. Its unique mechanism of action and established efficacy have made it a cornerstone in the treatment protocols for specific solid tumors and hematological malignancies, despite its potential for significant side effects requiring careful patient monitoring.

Uses

• Treatment of metastatic malignant melanoma.
• Part of combination chemotherapy for Hodgkin's lymphoma.
• Management of soft tissue sarcomas.
• Used in neuroblastoma treatment protocols.

Directions For Use

Administer intravenously by a qualified healthcare professional. Dosage and infusion rate are determined by the physician.

Benefits

• Established efficacy in metastatic melanoma.
• Key component in Hodgkin's lymphoma regimens.
• Can induce tumor regression in sensitive cancers.
• Available as an intravenous formulation for precise dosing.
• Part of standard treatment protocols for specific malignancies.
• Contributes to improved survival in certain patient populations.

Side Effects

• Nausea and vomiting (often severe)
• Myelosuppression (low blood counts: leukopenia, thrombocytopenia, anemia)
• Flu-like syndrome (fever, myalgia, malaise)
• Anorexia
• Alopecia (hair loss)
• Photosensitivity
• Injection site pain/irritation
• Hepatotoxicity (liver damage)
• Renal dysfunction (rare)
• Neurotoxicity (rare)
• Hypersensitivity reactions
• Secondary malignancies (long-term risk)

Safety Measures

• Alcohol - Avoid alcohol during treatment as it may exacerbate liver toxicity and gastrointestinal side effects.
• Pregnancy - Contraindicated in pregnancy due to significant risk of fetal harm and teratogenicity.
• Breastfeeding - Absolutely contraindicated during treatment and for a period after due to excretion into breast milk and potential harm to the infant.
• Liver - Use with extreme caution and potential dose reduction in patients with impaired liver function due to metabolic activation and hepatotoxicity risk.
• Kidney - Use with caution in patients with renal impairment; dosage adjustments may be necessary based on creatinine clearance.
• Lung - Monitor for pulmonary toxicity, though it is a rare side effect.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.